Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response

Abstract

Over the past several years remarkable therapeutic responses have been obtained with immunomodulatory monoclonal antibodies(mAbs), both in mice \cite{10,18,20,48,54,61} and human cancer patients \cite{1,3,14,28,30,39,80}. However, complete regressions and cures are infrequent and not predictable and some tumor types respond much worse than others. As an attempt to increase curability, we have investigated in mouse models the therapeutic efficacy of several mAb combinations, focusing on anti-PD-1/CTLA-4/CD137 and anti-PD-1/CTLA-4/CD137/CD19, and we have also combined mAbs with the chemotherapeutic drug cisplatin. Our data demonstrate an important contribution of anti-CD19 mAb to therapeutic efficacy, they show that intratumoral delivery of the mAbs is therapeutically more effective than systemic delivery, and that there is synergy when the mAbs are combined with cisplatin. In an attempt to improve predictability, we developed an in vitro model that may also be employed to search for novel immunomodulatory agents and combinations. This article reviews our data and discusses what is known about the underlying mechanisms.

Keywords

Tumor immunotherapy immunomodulatory antibody checkpoint inhibitors mouse models immunosuppression autoimmunity

References

Ascierto

et al., Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies, Semin Oncol37 (2010), 508-516.

Baban

et al., A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell supppression via type I IFN signaling following B7 ligation, International Immunology17 (2005), 909-919.

Balachandran

V.P.

, Cavnar

M.J.

, Zeng

, Bamboat

Z.M.

, Ocuin

L.M.

, Obaid

, Sorenson

E.C.

, Popow

, Ariyan

, Rossi

, Besmer

, Guo

, Antonescu

C.R.

, Taguchi

, Yuan

, Wolchok

J.D.

, Allison

J.P.

and DeMatteo

R.P.

, Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido, Nat Med17(9) (2011), 1094-1100.

Balkwill

and Mantovani

, Inflammation and cancer: Back to virchow? Lancet357(9255) (2001), 539-545.

Bielas

J.H.

et al., Human cancers express a mutator phenotype, Proc Natl Acad Sci103 (2006), 18238-18242.

Boon

et al., Tumor antigens recognized by T lymphocytes, Annu Rev Immunol12 (1994), 337-365.

Byrne

W.L.

, Mills

K.H.G.

, Lederer

J.A.

and O'Sullivan

G.C.

, Targeting regulatory T cells in cancer, Cancer Res71(22) (2011), 6915-6920.

Chen

et al., Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4, Cell71(7) (1992), 1093-102.

Chen

et al., Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16, J Immunol148(8) (1992), 2617-2621.

10.

Chen

L.P.

, Lymphocyte co-signal molecules in cancer immunotherapy, J Immunother29 (2006), 664.

11.

Chen

L.P.

et al., Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen, Proc Natl Acad Sci U S A88(1) (1991), 110-114.

12.

Coley

, Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases, Bull Johns Hopkins Hos7 (1896), 157-000.

13.

Coussens

L.M.

and Werb

, Inflammation and cancer, Nature420(6917) (2002), 860-867.

14.

Couzin-Frankel

, Cancer immunotherapy, Science342 (2013), 1432-1433.

15.

Cubillos-Ruiz

J.R.

et al., Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity, J Clin Invest119(8) (2009), 2231-2244.

16.

Curran

et al., Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation and cytokine production, PloS One6(4 e19499) (2011).

17.

Cuzick

, Meijer

C.J.

and Walboomers

J.M.

, Screening for cervical cancer, Lancet351(9113) (1998), 1439-1440.

18.

Dai

et al., Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation, J Immunother36 (2013), 248-257.

19.

Dai

et al., Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation, J Immunother36(4) (2013), 248-257.

20.

Dai

et al., Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies, Clin Cancer Res21 (2014), 1127-1138.

21.

Dai

et al., An in vitro model that predicts the therapeutic efficacy of immunomodulatory antibodies, J Immunother39 (2016), 298-305.

22.

Dai

et al., Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies, Clin Cancer Res21(5) (2015), 1127-1138.

23.

De Monte

, Reni

, Tassi

, Clavenna

, Papa

, Recalde

, Braga

, Di Carlo

, Doglioni

and Protti

M.P.

, Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer, J Exp Med208(3) (2011), 469-478.

24.

de Visser

, Eichten

and Coussens

L.M.

, Paradoxical roles of the immune system during cancer development, Nat Rev Cancer6 (2006), 24-37.

25.

DiLillo

, Yanaba

and Tedder

T.F.

, B cells arae required for optimal CD4+ and CD8+ T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice, J Immunol184 (2010), 4006-4016.

26.

Feng

et al., Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma, Gynecol Oncol127(2) (2012), 412-419.

27.

Flies

D.B.

et al., Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy, Yale J Biol Med84 (2011), 409-421.

28.

Galon

et al., The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures, Immunity39 (2013), 11-26.

29.

Grivennikov

S.I.

, Greten

F.R.

and Karin

, Immunity, inflammation, and cancer, Cell140(6) (2010), 883-899.

30.

Hamid

et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med369(2) (2013), 134-144.

31.

Hellstrom

and Hellstrom

K.E.

, Cell-bound immunity to autologous and syngeneic mouse tumors induced by methylcholanthrene and plastic discs, Science156(3777) (1967), 981-983.

32.

Hellstrom

et al., Demonstration of cell-bound and humoral immunity against neuroblastoma cells, Proc Nat Acad Sci60 (1968), 1231-1238.

33.

Hellstrom

et al., Cellular and humoral immunity to different types of human neoplasms, Nature220(5174) (1968), 1352-1354.

34.

Hellstrom

et al., CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer, Proc Natl Acad Sci U S A98 (2001), 6783-6788.

35.

Hellstrom

K.E.

and Hellstrom

, Cellular immunity against tumor specific antigens, Adv Cancer Res12 (1969), 167-223.

36.

Hellstrom

K.E.

and Hellstrom

, Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens, Adv Immunol18 (1974), 209-277.

37.

Hewitt

H.B.

, Blake

E.R.

and Walder

A.S.

, A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin, Br J Cancer33(3) (1976), 241-259.

38.

Hirano

et al., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity, Cancer Res65 (2005), 1089-1096.

39.

Hodi

et al., Improved survival with ipilimumab in patients with metastatic melanoma, New Engl J Med363 (2010), 711-723.

40.

Ito

et al., TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand, J Exp Med202(9) (2005), 1213-1223.

41.

Kandalaft

L.E.

, Powell

D.J.

, Singh

and Coukos

, Immunotherapy for ovarian cancer: What's next? J Clin Oncol29(7) (2011), 925-933.

42.

Kenter

G.G.

et al., Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia, N Engl J Med361(19) (2009), 1838-1847.

43.

Kim

Y.J.

et al., Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses, Eur J Immunol28(3) (1998), 881-890.

44.

Kiviat

N.B.

et al., Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic, J Infect Dis159(2) (1989), 293-302.

45.

Klein

and Klein

, Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: Contrasting consequences of host versus tumor evolution, Proc Natl Acad Sci U S A74(5) (1977), 2121-2125.

46.

Klein

et al., Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host, Cancer Res20 (1960), 1561-1572.

47.

Kono

et al., Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer, Clin Cancer Res2 (1996), 1825-1828.

48.

Leach

D.R.

, Krummel

M.F.

and Allison

J.P.

, Enhancement of antitumor immunity by CTLA-4 blockade, Science271(5256) (1996), 1734-1736.

49.

Lei

et al., Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy, J Am Chem Soc132 (2010), 6906-6907.

50.

Linsley

P.S.

and Ledbetter

J.A.

, The role of the CD28 receptor during T cell responses to antigen, Annu Rev Immunol11 (1993), 191-212.

51.

Liu

et al., Inhibition of TGFbeta 1 makes nonimmunogenic tumor cells effective for therapeutic vaccination, J Immunother32 (2009), 232-239.

52.

Massacand

J.C.

et al., Helminth products bypass the need for TSLP in Th2 immune responses by directly modulating dendritic cell function, Proc Natl Acad Sci U S A106(33) (2009), 13968-13973.

53.

Melero

et al., NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies, Cell Immunol190(2) (1998), 167-172.

54.

Melero

et al., Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors, Nat Med3(6) (1997), 682-685.

55.

Mittler

R.S.

et al., Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy, J Exp Med190(10) (1999), 1535-1540.

56.

Mizoguchi

et al., Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice [see comments], Science258(5089) (1992), 1795-1798.

57.

Munn

D.H.

, Indoleamine 2, 3-dioxygenase, Tregs and Cancer, Curr Med Chem18(15) (2011), 2240-2246.

58.

Nakagomi

et al., Decreased expression of the signal-transducing z chains in tumor-infiltrating T cells and NK cells of patients with colorectal carcinoma, Cancer Res53 (1993), 5610-5612.

59.

Nelson

, CD20+ B cells: the other tumor-infiltrating lymphocytes, J Immunol185(9) (2010), 4977-4982.

60.

Ovestad

I.T.

et al., Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression, Mod Pathol23(9) (2010), 1231-1240.

61.

Pardoll

, The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer12 (2012), 252-264.

62.

Pedroza-Gonzalez

, Xu

, Wu

T.C.

, Aspord

, Tindle

, Marches

, Gallegos

, Burton

E.C.

, Savino

, Hori

, Tanaka

, Zurawski

, Bover

, Liu

Y.J.

, Banchereau

and Palucka

A.K.

, Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation, J Exp Med208(3) (2011), 479-490.

63.

Prehn

and Main

, Immunity to methylcholanthrene-induced sarcomas, J Natl Cancer Inst18 (1957), 769-778.

64.

Price

J.E.

, Tarin

and Fidler

, Influence of organ microenvironment on pigmentation of a metastatic murine melanoma, Cancer Res48 (1988), 2258-2264.

65.

Ramakrishna

et al., Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells, Int Immunol15(6) (2003), 751-763.

66.

Ravetch

and Bolland

, IgG Fc receptors, Ann Rev Immunol19 (2001), 275-290.

67.

Sanderson

R.D.

and Børset

, Syndecan-1 in B lymphoid malignancies, Ann Hematol81(3) (2002), 125-135.

68.

Santin

A.D.

et al., Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer, Gynecol Obstet Invest51(4) (2001), 254-261.

69.

Schondorf

et al., Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients, J Soc Gynecol Investig5(2) (1998), 102-107.

70.

Sedlacek

T.V.

, Advances in the diagnosis and treatment of human papillomavirus infections, Clin Obstet Gynecol42(2) (1999), 206-220.

71.

Selvaraj

, Fifadara

, Nagarajan

, Cimino

and Wang

, Functional regulation of human neutrophil Fc gamma receptors, Immunol Res29(1-3) (2004), 219-230.

72.

Sherman

M.E.

et al., Toward objective quality assurance in cervical cytopathology, correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types, Am J Clin Pathol102(2) (1994), 182-187.

73.

Sheu

B.C.

et al., Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer, J Immunol167(5) (2001), 2972-2978.

74.

Sjogren

H.O.

, Studies on specific transplantation resistance against polyoma virus-induced tumors. IV. Stability of the polyoma cell antigen, J Natl Cancer Inst32 (1964), 661-666.

75.

Stoler

M.H.

and Schiffman

, Interobserver reproducibility of cervical cytologic and histologic interpretations: Realistic estimates from the ASCUS-LSIL Triage Study, Jama285(11) (2001), 1500-1505.

76.

van den Hende

et al., Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4$+$ memory T cell responses, J Infect Dis202(8) (2010), 1200-1211.

77.

Vermeij

et al., Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen, Curr Pharm Des18(25) (2012), 3804-3811.

78.

Wei

et al., Silencing of the TGFbeta1 gene increases the immunogenicity of cells from human ovarian carcinoma, J Immunother35 (2012), 267-275.

79.

Wei

et al., Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin, PLOS One8(12) (2013), e84927.doiL10.1371/journal.pone0084927.

80.

Wolchok

J.D.

et al., Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med369(2) (2013), 122-133.

81.

Yang

S.C.

et al., Melanoma cells transfected to express CD83 induce anti-tumor immunity that can be increased by also engaging CD137, Proc Natl Acad Sci101 (2004), 4990-4995.

82.

Yang

et al., Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment, Cancer Res67(5) (2007), 2339-2344.

83.

et al., Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB, Nat Med8(4) (2002), 343-348.

84.

Zhang

et al., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N Engl J Med348 (2003), 203-213.

85.

Ziegler

S.F.

and Artis

, Sensing the outside world: TSLP regulates barrier immunity, Nat Immunol11(4) (2010), 289-293.

86.

Zitvogel

et al., Immunological aspects of cancer chemotherapy, Nat Rev Immunol8 (2008), 59-73.

87.

Zou

, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat Rev Cancer5(4) (2005), 263-274.

88.

zur Hausen

, Papillomaviruses in the causation of human cancers - a brief historical account, Virology384(2) (2009), 260-265.

89.

zur Hausen

, Viruses in human cancers, Eur J Cancer35(14) (1999), 1878-1885.